Total
|
68
|
14
| |
Sex
| | |
0.045¶
|
Male
|
52 (76.5)
|
7 (50.0)
| |
Female
|
16 (23.5)
|
7 (50.0)
| |
Pathological type
| | |
0.133&
|
WHO type II
|
2 (2.9)
|
2 (14.3)
| |
WHO type III
|
66 (97.1)
|
12 (85.7)
| |
T stagea
| | |
0.334#
|
T1
|
0 (0)
|
1 (7.1)
| |
T2
|
24 (35.3)
|
4 (28.6)
| |
T3
|
35 (51.5)
|
7 (50.0)
| |
T4
|
9 (13.2)
|
2 (14.3)
| |
N stagea
| | |
0.974#
|
N1
|
13 (19.1)
|
3 (21.4)
| |
N2
|
34 (50.0)
|
7 (50.0)
| |
N3
|
21 (30.9)
|
4 (28.6)
| |
Clinical stagea
| | |
0.179¶
|
II
|
7 (10.3)
|
4 (28.6)
| |
III
|
34 (50.0)
|
5 (35.7)
| |
IV
|
27 (39.7)
|
5 (35.7)
| |
EBV DNA before treatment (copies/mL)
|
0.252¶
|
≤ 4000
|
23 (33.8)
|
7 (50.0)
| |
> 4000
|
45 (66.2)
|
7 (50.0)
| |
EBV DNA before surgery (copy/mL) < 0.001#
|
0
|
32 (47.1)
|
14 (100)
| |
> 0
|
36 (52.9)
|
0 (0.0)
| |
VCA-IgA
| | |
0.988¶
|
< 1:320
|
29 (42.6)
|
6 (42.9)
| |
≥ 1:320
|
39 (57.4)
|
8 (57.1)
| |
EA-IgA
| | |
0.196¶
|
< 1:20
|
27 (39.7)
|
3 (21.4)
| |
≥ 1:20
|
41 (60.3)
|
11 (78.6)
| |
Size of lymph node 0.747¶
|
< 3 cm
|
42 (61.8)
|
8 (57.1)
| |
≥ 3 cm
|
26 (38.2)
|
6 (42.9)
| |
Lymph node invasion 1.000#
|
Yes
|
4 (5.9)
|
0 (0.0)
| |
No
|
64 (94.1)
|
14 (100)
| |
Lymph node necrosis 0.865¶
|
Yes
|
16 (23.5)
|
3 (21.4)
| |
No
|
52 (76.5)
|
11 (78.6)
| |
Treatment for cervical lymphadenopathy
|
0.285#
|
Surgery alone
|
54 (79.4)
|
14 (100)
| |
Surgery + chemotherapy
|
9 (13.2)
|
0 (0.0)
| |
Surgery + radiotherapy
|
5 (7.5)
|
0 (0.0)
| |
Treatment for NPC
| | |
0.957#
|
Radiotherapy alone
|
4 (5.9)
|
1 (7.15)
| |
CCRT
|
22 (32.4)
|
5 (35.7)
| |
NAC + CCRT
|
38 (55.9)
|
7 (50.0)
| |
CCRT + AC
|
4 (5.9)
|
1 (7.15)
| |
Irradiation technique
| | |
1.000&
|
2D-RT
|
7 (10.3)
|
1 (7.1)
| |
IMRT
|
61 (89.7)
|
13 (92.9)
| |